🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

biote Corp. BTMD R2K

Healthcare · Medical Care Facilities · United States
https://www.biote.com

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and meet other administrative requirements; inventory management software to facilitate ordering and inventory control; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female patients. The company was founded in 2012 and is headquartered in Irving, Texas.

READ MORE ›
$2.00
-42.20% 1Y

Market & Price

Market Cap
$71.11M
Current Price
$2.00
High / Low (52W)
$4.55 / $1.30
Beta
1.71

Valuation

Stock P/E
4.65
Industry PE
23.65
Forward P/E
3.51
PEG Ratio
-
Book Value
$-1.87
Price to Book
-1.07
P/S
0.38
EV/EBITDA
5.23
Dividend Yield
-

Profitability & Returns

ROCE
77.52%
ROE
-
ROA
17.81%
Profit Margin
8.29%
Op Margin
9.78%
EPS (Latest Qtr)
$0.06
EPS (TTM)
$0.43

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
0.45
Current Ratio
1.29
Debt
$108.42M
Total Assets
$107.61M
Current Assets
$54.67M
Working Capital
$9.68M

Ownership

Promoter Holding
10.39%
Chg in Prom Hold
-
FII / Inst Holding
66.62%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$171.90M
Total Revenue (TTM)
$188.16M
EBITDA
$32.86M
Free Cash Flow
$-4.73M
Operating Cash Flow
$32.63M
Shares Outstanding
30.33M
Gross Margin
70.12%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
5.23%
Profit 5Y
963.67%
Revenue (YoY)
-8.30%
Earnings (YoY)
-83.80%

PROS

  • Healthy ROCE of 77.5%.
  • Profit CAGR of 963.7% over 5 years.

CONS

  • Trading 56.0% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 BTMD biote Corp. R2K 2.00 4.65 $71.11M - 77.52% - 5.23% 963.67%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -34.75M35.57M37.14M41.36M41.97M44.84M49.26M45.56M46.80M49.17M51.38M48.99M48.86M47.96M46.41M44.94M
Cost of Revenue ------------12.61M13.88M13.54M14.84M13.98M
Gross Profit ------------36.38M34.99M34.42M31.57M30.95M
Operating Expenses ------------26.69M24.22M26.15M24.74M27.79M
Operating Income -107.88K10.26M8.98M9.76M-85.60M7.82M7.88M7.67M7.60M10.43M6.23M12.18M9.69M10.77M8.27M6.83M3.17M
EBITDA ------------21.22M9.84M12.14M9.03M6.29M
Interest Expense ------------2.90M2.85M2.73M2.47M1.97M
Pretax Income ------------17.45M6.08M8.45M5.60M3.34M
Tax Provision ------------1.62M2.15M-765.00K2.99M662.00K
Net Income -3.94M13.24M-1.17M-2.61M15.00K-6.80M-5.14M7.53M-4.16M-7.09M10.70M13.72M3.19M8.19M1.95M2.28M
Diluted EPS -----0.340.00-0.39-0.250.24-0.12-0.210.330.370.100.220.060.06

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -164.96M185.36M197.19M192.22M
Cost of Revenue -54.58M57.88M58.13M54.86M
Gross Profit -110.38M127.48M139.06M137.36M
Operating Expenses -171.10M98.83M107.45M101.81M
Operating Income --60.72M28.66M31.61M35.55M
EBITDA -7.96M9.23M15.59M52.22M
Interest Expense -4.05M6.36M11.00M10.96M
Pretax Income -1.71M-123.00K1.02M37.58M
Tax Provision -388.00K2.68M970.00K5.99M
Net Income --969.00K3.32M3.16M27.05M
Diluted EPS 4.31-0.120.130.09-

Compounded Sales Growth

5 Years:5.23%
1 Year:-8.30%

Compounded Profit Growth

5 Years:963.67%
1 Year:-83.80%

Stock Price Performance

1 Year:-42.20%
6 Months:-21.26%
3 Months:-5.66%
1 Month:-9.91%

Balance Sheet (Annual)

Figures in USD.

Metric Jul 2020Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -147.50K-111.64M155.29M122.37M107.61M
Current Assets ---101.18M122.34M68.13M54.67M
Cash & Equivalents -1.59K-79.23M89.00M39.34M24.12M
Inventory ---11.18M17.31M14.85M19.06M
Receivables ---6.95M6.81M7.63M6.87M
Total Liabilities -122.50K-169.92M191.84M224.57M158.01M
Current Liabilities -122.50K-18.77M22.21M51.51M44.99M
Long Term Debt ---112.09M106.63M101.20M100.78M
Total Debt ---120.43M114.87M110.86M109.92M
Total Equity 025.00K--44.46M-29.40M-105.93M-58.54M
Shares Outstanding ---11.24M35.84M33.07M32.30M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow --9.16M26.88M45.24M35.19M
Investing Cash Flow --1.84M-2.71M-18.80M-6.86M
Financing Cash Flow -63.46M-14.38M-76.08M-43.55M
Capital Expenditure --1.84M-2.71M-6.96M-6.86M
Free Cash Flow --10.99M24.17M38.29M28.33M
Net Change in Cash -52.47M9.79M-49.64M-15.22M
Share Buybacks ---5.60M3.37M
Dividends Paid 11.40M12.89M8.69M4.74M1.73M

Ratios (Annual)

Figures in %.

Metric Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -66.9%68.8%70.5%71.5%
Operating Margin % --36.8%15.5%16.0%18.5%
Net Margin % --0.6%1.8%1.6%14.1%
ROE % -2.2%-11.3%-3.0%-46.2%
ROCE % --65.4%21.5%44.6%56.8%

Shareholding Pattern

Insiders
10.39%
Institutions
66.62%
Public Float
74.34%

Top Institutional Holders

#Holder% HeldSharesValue
1 325 Capital Llc 14.32% 4.55M $9.10M
2 Bandera Partners LLC 6.51% 2.07M $4.13M
3 Blackrock Inc. 5.48% 1.74M $3.48M
4 Vanguard Capital Management LLC 3.51% 1.11M $2.23M
5 Acadian Asset Management. LLC 2.20% 697.86K $1.40M
6 State Street Corporation 2.04% 646.95K $1.29M
7 Geode Capital Management, LLC 1.94% 615.66K $1.23M
8 Dimensional Fund Advisors LP 1.71% 543.49K $1.09M
9 Globeflex Capital L P 0.86% 272.40K $544.80K
10 Northern Trust Corporation 0.85% 269.11K $538.23K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for BTMD

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks